Todd Beckman
CEO

Verb Biotics develops targeted probiotic strains and bioactive ingredients to enhance microbiome health, addressing issues related to digestive health, stress, and immune response. Their function-first approach utilizes intentional research to create clinically-validated solutions for specific health needs in food, beverage, and supplement applications.
Raised to date
$60MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CEO
Existing probiotic solutions often lack specificity and proven efficacy, relying on generic strains and colony-forming units (CFUs) as a proxy for potency. Many products fail to address specific health needs with targeted mechanisms of action, leading to inconsistent results for consumers.
Verb Biotics develops function-first bioactives, including probiotics and postbiotics, designed to deliver specific health benefits by targeting the microbiome. The company utilizes a science-driven approach, starting with the desired health outcome and then identifying and scaling bioactive solutions that provide a specific mechanism of action. Their ingredients are developed to address common and complex health states, such as digestive health, stress and mood, healthy aging, sports recovery, and women’s health. Verb Biotics combines science, biotechnology, and intentional development to deliver clinically-validated ingredients for food, beverage, and supplement brands.
Verb Biotics serves food, beverage, and supplement brands looking to differentiate their products with clinically-validated, function-first microbiome solutions.